DigestRedComo funciona
Red
/
Empresas
Sp
No verificado

SpringWorks Therapeutics, Inc.

Sobre qué escribimos

Anuncios brevesBiotecnologíaFinanzasMedicina Salud Bienestar

8 Comunicados de prensa

Ver todos los comunicados de prensa
20/10/2025
Biotecnología
Anuncios breves
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
Fuente
SpringWorks Therapeutics, Inc.
Editor
GLOBENEWSWIRE
1.00
0
18/08/2025
Biotecnología
Medicina Salud Bienestar
Anuncios breves
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
Fuente
SpringWorks Therapeutics, Inc.
Editor
GLOBENEWSWIRE
1.00
0
18/07/2025
Biotecnología
Medicina Salud Bienestar
Finanzas
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Fuente
SpringWorks Therapeutics, Inc.
Editor
GLOBENEWSWIRE
1.00
0
20/06/2025
Biotecnología
Medicina Salud Bienestar
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
Fuente
SpringWorks Therapeutics, Inc.
Editor
GLOBENEWSWIRE
1.00
0
24/05/2025
Biotecnología
Medicina Salud Bienestar
SpringWorks Therapeutics recibe un dictamen positivo del CHMP para el uso de mirdametinib en el tratamiento de la NF1-NP en pacientes adultos y pediátricos
Fuente
SpringWorks Therapeutics, Inc.
Editor
GLOBENEWSWIRE
1.00
0
24/05/2025
Biotecnología
Medicina Salud Bienestar
SpringWorks Therapeutics: CHMP valuta positivamente Mirdametinib per il trattamento di pazienti adulti e pediatrici affetti da NF1-PN
Fuente
SpringWorks Therapeutics, Inc.
Editor
GLOBENEWSWIRE
1.00
0
24/05/2025
Biotecnología
Medicina Salud Bienestar
SpringWorks Therapeutics reçoit un avis favorable du CMUH pour l’utilisation du mirdamétinib pour le traitement des patients adultes et pédiatriques atteints de NF1-PN
Fuente
SpringWorks Therapeutics, Inc.
Editor
GLOBENEWSWIRE
1.00
0
23/05/2025
Biotecnología
Medicina Salud Bienestar
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Fuente
SpringWorks Therapeutics, Inc.
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0